APR 03, 2018 8:27 PM PDT

Two-Drug Strategy for Non-Small Cell Lung Cancer (NSCLC)

WRITTEN BY: Nouran Amin

According to the National Cancer Institute, lung cancer is the most common cause of cancer death for both men and women in the U.S. More specifically, non-small cell lung cancer (NSCLC) encompasses 85% of all lung cancers.

Investigators seeking new treatment options for patients of lung cancer have found a combination of drugs that are effective for NSCLC specifically. These drugs target epidermal growth factor receptor (EGFR) and tumor necrosis factor (TNF), the targeting works to effectively inhibit the cancer from using TNF as way to escape and allowing the cancer to be sensitive to the EGFR treatment.

"There has been a tremendous effort over the past several years to block EGFR as a treatment for lung cancer, but this therapy only works in a small subset of patients. The cancer fights back with a bypass pathway," explains lead researcher Dr. Amyn Habib with the Harold C. Simmons Comprehensive Cancer Center at UT Southwestern as well as a staff physician at the Dallas Veterans Affairs Medical Center. "Blocking both of these proteins could be a treatment that is beneficial for the majority of lung cancer patients.” These research findings stem from the same combination of drug treatments that were found to be successful in a glioblastoma mouse model.Bottom Rows: Tumors treated w/ two-drug strategy. Top Rows: Tumors left untreated or w/ a single treatment. Credit: UT Southwestern via Science Daily

Furthermore, these anti-EGFR/TNF two-strategy drugs were found to be well tolerated and with few side effects which was because they worked to target specific molecules within cancer cells. Thus, anti-EGFR/TNF drugs are more advantageous than traditional chemotherapeutic treatments which have unpleasant side-effects on a patient.

Investigators will continue their research for a phase 2 clinical trial of using the two-drug strategy; which has already been approved by the FDA. The prospective clinical studies are being planned to test the two-drug treatment in lung cancer patients as well as glioblastomas. "If this strategy is effective, then it might be broadly applicable not only against lung cancer but also against other cancers that express EGFR, which include brain, colon, and head and neck cancers," says lead clinical studies leader Dr. Gerber, an Associate Professor of Internal Medicine and Clinical Sciences.

Until recently, EGFR inhibitors were studied to be effective at treating a small percentage of non-small cell lung cancers that have a variant form of EGFR. However, with two-drug strategy, treatment could be effective for all forms of non-small cell lung cancers.

The research was published in the Journal of Clinical Investigation.

Source: Journal of Clinical Investigation, Science Daily

About the Author
  • Nouran earned her BS and MS in Biology at IUPUI and currently shares her love of science by teaching. She enjoys writing on various topics as well including science & medicine, global health, and conservation biology. She hopes through her writing she can make science more engaging and communicable to the general public.
You May Also Like
OCT 27, 2020
Cardiology
Boron Could Prevent Myocardial Fibrosis and Assist in Recovery
OCT 27, 2020
Boron Could Prevent Myocardial Fibrosis and Assist in Recovery
When you pass by the nutrition section at the local grocery store, there is a chance you’ll come across row upon r ...
OCT 29, 2020
Cardiology
Treating Cardiovascular Calcification at the Source
OCT 29, 2020
Treating Cardiovascular Calcification at the Source
The term cardiovascular disease covers a broad array of health problems. Everyone tends to think of heart attacks or hyp ...
NOV 12, 2020
Immunology
The Enzyme That Keeps Viruses In Stealth Mode
NOV 12, 2020
The Enzyme That Keeps Viruses In Stealth Mode
Some viral infections just don’t go away. The hepatitis C virus, for instance, can result in life-long chronic inf ...
DEC 01, 2020
Immunology
Scar-Free Healing Starts With Mobilizing the Immune System
DEC 01, 2020
Scar-Free Healing Starts With Mobilizing the Immune System
Thanks to a new hydrogel biomaterial developed by researchers at Duke University, we are one step closer to the holy gra ...
DEC 21, 2020
Drug Discovery & Development
Drug Increases Vaccine Responses
DEC 21, 2020
Drug Increases Vaccine Responses
A drug was found to increase the effects of vaccine responses in older adults. The drug works by removing cellular debri ...
DEC 24, 2020
Drug Discovery & Development
New Gene Therapy Targets Deafness
DEC 24, 2020
New Gene Therapy Targets Deafness
New gene therapy study addresses treatment methods for deafness. "In this study we focused on genetic deafness caus ...
Loading Comments...